$AIMSep 2, 2026, 12:43 PMAI processed
AIM wins European & UK patents for Ampligen in Long COVID through 2041
AI Summary
AIM ImmunoTech announced patents in multiple European countries and the U.K. covering use of Ampligen (tdsRNA) to treat Long COVID, with protection expected through June 2041 after the nine‑month opposition period closed with no challenges; claims include specific dosing regimens and intranasal, intravenous and inhalation delivery. The company says the grants expand its global Ampligen IP estate and complement a recently issued U.S. patent for Ampligen+pembrolizumab, and cites >1,200 patients and 100,000+ doses of clinical experience with favorable safety.
Positives
- Patent protection across major European countries and the U.K. through June 2041 with no opposition filed
- Claims explicitly cover Ampligen as a tdsRNA including specific dosing and intranasal, IV and inhalation delivery routes
- Complements a recent U.S. patent for an Ampligen+pembrolizumab cancer combination, expanding multi‑indication IP footprint
Negatives
- Patent grants do not equate to regulatory approval or proven clinical efficacy for Long COVID
- Efficacy for Long COVID remains unestablished despite cited clinical experience
- Geographic coverage limited to the listed European jurisdictions and the U.K., not worldwide exclusivity